drugset / Trial / NCT04973566
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
RandomizedParallel-groupOpen-labelOther
Summary
The primary purpose of this study is to assess the effect of nipocalimab on the pharmacokinetic (PK) of etanercept (Part 1); and to assess the effect of hydroxychloroquine (HCQ) on total serum immunoglobin G (IgG) reduction by nipocalimab (Part 2) in healthy participants.
Timeline
- Start
- 2021-08-31
- Primary completion
- 2022-05-27
- Completion
- 2022-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Hydroxychloroquine | Small molecule | — | Oral |
| Subject | Nipocalimab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.